調査レポートカテゴリー： MarketsandMarkets, 世界, 医療/バイオ

Stem Cell Assays Market by Type (Viability, Proliferation, Differentiation, Apoptosis), Cell Type (Mesenchymal, iPSCs, HSCs, hESCs), Product & Service (Instrument), Application (Regenerative Medicine, Clinical Research), End User - Global Forecast to 2027

幹細胞アッセイのグローバル市場予測（～2027）：生存率、増殖、分化、アポトーシス

◆タイトル：Stem Cell Assays Market by Type (Viability, Proliferation, Differentiation, Apoptosis), Cell Type (Mesenchymal, iPSCs, HSCs, hESCs), Product & Service (Instrument), Application (Regenerative Medicine, Clinical Research), End User - Global Forecast to 2027
◆商品コード：BT4628-22
◆調査・発行会社：MarketsandMarkets
◆発行日：2022年6月21日
◆ページ数：332
◆レポート形式：PDF / 英語
◆納品方法：Eメール（受注後24時間以内）
◆調査対象地域：グローバル
◆産業分野：バイオ
◆販売価格オプション（消費税別）

Single User（1名様閲覧）	USD4,950 ⇒換算￥0	見積依頼/購入/質問フォーム
Multi User (Five User)	USD6,650 ⇒換算￥0	見積依頼/購入/質問フォーム
Corporate License (全社内共有可)	USD8,150 ⇒換算￥0	見積依頼/購入/質問フォーム

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※商品の納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。（振込先：三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。（但し、対応範囲は弊社で判断）
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

マーケッツアンドマーケッツ社は、世界の幹細胞アッセイ市場規模が、2022年19億ドルから2027年45億ドルまで年平均17.7％成長すると予測しています。本調査資料では、幹細胞アッセイの世界市場について総合的に調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、種類別（生存率/細胞毒性、分離＆精製、細胞識別、増殖、分化）分析、細胞種類別（成体幹細胞、ヒト胚性幹細胞）分析、製品・サービス別（機器、キット、サービス）分析、用途別（再生医療＆治療法開発、創薬＆開発、臨床研究）分析、地域別分析、競争状況、企業情報などの内容をまとめております。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・世界の幹細胞アッセイ市場規模：種類別（生存率/細胞毒性、分離＆精製、細胞識別、増殖、分化）
・世界の幹細胞アッセイ市場規模：細胞種類別（成体幹細胞、ヒト胚性幹細胞）
・世界の幹細胞アッセイ市場規模：製品・サービス別（機器、キット、サービス）
・世界の幹細胞アッセイ市場規模：用途別（再生医療＆治療法開発、創薬＆開発、臨床研究）
・世界の幹細胞アッセイ市場規模：地域別
・競争状況
・企業情報

“The stem cell assays market is projected to reach USD 4.5 Billion by 2027 from USD 1.9 Billion in 2022, at a CAGR of 17.7% during the forecast period.”
The growth of the market is projected to be driven by collaborations and agreements among market players for stem cell assay products & services, launch of new stem cell analysis systems such as flow cytometers and increase in R&D expenditure by biopharmaceutical and biotechnology companies.

“The viability/cytotoxicity assays accounted for the largest share of the type segment in the stem cell assays market in 2021.”
Cell viability assays help to determine the number of live and dead cells in a culture medium. The viability/cytotoxicity assays includes various types such as tetrazolium reduction assays, resazurin cell viability assays, calcein-AM cell viability assays, and other viability/cytotoxicity assays. The cell viability/cytotoxicity market is likely to be driven by rise R&D spending on stem cell research, increase in demand for stem cell assays in drug discovery and development of new stem cell therapies..

“The adult stem cells segment accounted for the largest share of the cell type segment in the stem cell assays market in 2021.”
The adult stem cells account for the largest share of the stem cell assays market. The adult stem cells include mesenchymal stem cells, induced pluripotent stem cells, hematopoietic stem cells, umbilical cord stem cells, and neural stem cells. The growth of adult stems cells segment is driven by increasing usage of adult stem cells in regenerative medicine and development of advanced therapies.
Key players in the stem cell assays market include Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Danaher (US), Becton, Dickinson and Company (US), Bio-Rad Laboratories (US), PerkinElmer (US), Agilent Technologies (US), Promega Corporation (US), Cell Biolabs (US), Miltenyi Biotec (Germany), STEMCELL Technologies (Canada), Bio-Techne Corporation (US), FUJIFILM Holdings Corporation (Japan), Charles River Laboratories (US), HemoGenix Inc. (US), Lonza Group (Switzerland), Takara Bio Inc. (Japan), Creative Bioarray (US), AAT Bioquest, Inc. (US), BPS Bioscience, Inc. (US), Enzo Biochem (US), PromoCell GmbH (Germany), Biotium (US), Geno Technology (US), Abcam plc (UK), and ReachBio Research Labs (US).

“Asia Pacific: The fastest-growing region in the stem cell assays market”
The Asia Pacific is estimated to be the fastest-growing segment of the market, owing to rising prevalence of cancer & other diseases, increasing R&D spending on biopharmaceutical projects and focus on developing stem cell based therapies. In this region, China and Japan are the largest markets.

The primary interviews conducted for this report can be categorized as follows:
• By Respondent: Supply Side- 80% and Demand Side – 20%
• By Designation: Managers- 45%, CXOs and Director level – 30%, and Executives – 25%
• By Region: North America -20%, Europe -10%, Asia-Pacific -55%, RoW -15%

List of Companies Profiled in the Report:
• Thermo Fisher Scientific Inc. (US)
• Merck KGaA (Germany)
• Danaher (US)
• Becton, Dickinson and Company (US)
• Bio-Rad Laboratories (US)
• PerkinElmer (US)
• Agilent Technologies (US)
• Promega Corporation (US)
• Cell Biolabs (US)
• Miltenyi Biotec (Germany)
• STEMCELL Technologies (Canada)
• Bio-Techne Corporation (US)
• FUJIFILM Holdings Corporation (Japan)
• Charles River Laboratories (US)
• HemoGenix Inc. (US)
• Lonza Group (Switzerland)
• Takara Bio Inc. (Japan)
• Creative Bioarray (US)
• AAT Bioquest, Inc. (US)
• BPS Bioscience, Inc. (US)
• Enzo Biochem (US)
• PromoCell GmbH (Germany)
• Biotium (US)
• Geno Technology (US)
• Abcam plc (UK)
• ReachBio Research Labs (US).

Research Coverage:
This report provides a detailed picture of the stem cell assays market. It aims at estimating the size and future growth potential of the market across different segments such as the product, functionality, formulation and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall stem cell assays market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, challenges, trends, and opportunities.

【レポートの目次】

1 INTRODUCTION 47
1.1 OBJECTIVES OF THE STUDY 47
1.2 MARKET DEFINITION 47
1.2.1 INCLUSIONS & EXCLUSIONS 48
1.3 MARKET SCOPE 49
1.3.1 MARKETS COVERED 49
1.3.2 YEARS CONSIDERED FOR THE STUDY 50
1.4 CURRENCY 50
1.5 LIMITATIONS 50
1.6 STAKEHOLDERS 51
1.7 SUMMARY OF CHANGES 51
2 RESEARCH METHODOLOGY 53
2.1 RESEARCH DATA 53
FIGURE 1 RESEARCH DESIGN 53
2.1.1 SECONDARY DATA 54
2.1.2 PRIMARY DATA 55
FIGURE 2 BREAKDOWN OF PRIMARIES, BY RESPONDENT, DESIGNATION, AND REGION 55
2.2 MARKET ESTIMATION METHODOLOGY 56
FIGURE 3 STEM CELL ASSAYS MARKET SIZE ESTIMATION
(SUPPLY-SIDE ANALYSIS), 2021 56
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1
(COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2021 57
2.2.1 INSIGHTS FROM PRIMARY EXPERTS 58
FIGURE 5 MARKET SIZE VALIDATION FROM PRIMARY SOURCES 58
2.3 MARKET GROWTH RATE PROJECTIONS 59
FIGURE 6 STEM CELL ASSAYS MARKET (SUPPLY SIDE): CAGR PROJECTIONS 60
FIGURE 7 STEM CELL ASSAYS MARKET (DEMAND SIDE):
GROWTH ANALYSIS OF DEMAND-SIDE FACTORS 61
2.3.1 DATA TRIANGULATION 62
FIGURE 8 DATA TRIANGULATION METHODOLOGY 62
2.4 RESEARCH ASSUMPTIONS 63
2.4.1 COVID-19 ASSUMPTIONS 63
2.5 RISK ANALYSIS 64
3 EXECUTIVE SUMMARY 65
FIGURE 9 STEM CELL ASSAYS MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION) 65
FIGURE 10 STEM CELL ASSAYS MARKET, BY CELL TYPE, 2022 VS. 2027 (USD MILLION) 66
FIGURE 11 STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE,
2022 VS. 2027 (USD MILLION) 66
FIGURE 12 STEM CELL ASSAYS MARKET, BY APPLICATION,
2022 VS. 2027 (USD MILLION) 67
FIGURE 13 STEM CELL ASSAYS MARKET, BY END USER, 2022 VS. 2027 (USD MILLION) 68
FIGURE 14 GEOGRAPHICAL SNAPSHOT OF STEM CELL ASSAYS MARKET 69
4 PREMIUM INSIGHTS 70
4.1 STEM CELL ASSAYS MARKET OVERVIEW 70
FIGURE 15 RISING AWARENESS ABOUT THERAPEUTIC POTENCY OF
STEM CELLS TO DRIVE MARKET GROWTH 70
4.2 NORTH AMERICA: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE AND COUNTRY (2021) 71
FIGURE 16 INSTRUMENTS SEGMENT ACCOUNTED FOR
LARGEST MARKET SHARE IN 2021 71
4.3 STEM CELL ASSAYS MARKET SHARE, BY TYPE, 2022 VS. 2027 71
FIGURE 17 VIABILITY/CYTOTOXICITY ASSAYS SEGMENT WILL CONTINUE
TO DOMINATE MARKET IN 2027 71
4.4 STEM CELL ASSAYS MARKET SHARE, BY APPLICATION, 2021 72
FIGURE 18 REGENERATIVE MEDICINE & THERAPY DEVELOPMENT SEGMENT
DOMINATED MARKET IN 2021 72
4.5 STEM CELL ASSAYS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 73
FIGURE 19 ASIA PACIFIC COUNTRIES TO REGISTER HIGHEST GROWTH RATE
FROM 2022 TO 2027 73
5 MARKET OVERVIEW 74
5.1 INTRODUCTION 74
5.2 MARKET DYNAMICS 74
FIGURE 20 STEM CELL ASSAYS MARKET: DRIVERS, RESTRAINTS,
OPPORTUNITIES, AND CHALLENGES 74
TABLE 1 STEM CELL ASSAYS MARKET: IMPACT ANALYSIS 75
5.2.1 DRIVERS 75
5.2.1.1 Increasing awareness about therapeutic potency of stem cells 75
5.2.1.2 Increasing funding for stem cell research 76
5.2.1.3 Rising demand for cell-based assays in drug discovery 77
5.2.1.4 Collaborations and agreements among market players for stem cell assay products & services 77
5.2.1.5 Rising incidence of cancer 78
TABLE 2 GLOBAL CANCER INCIDENCE, 2020 VS. 2040 78
5.2.2 RESTRAINTS 78
5.2.2.1 Issues in embryonic stem cell research 78
5.2.2.2 High cost of stem cell analysis instruments 78
5.2.3 OPPORTUNITIES 79
5.2.3.1 Emerging economies 79
5.2.3.2 Government initiatives to boost stem cell research 79

5.2.4 CHALLENGES 80
5.2.4.1 Lack of infrastructure for stem cell research in emerging economies 80
5.2.4.2 Dearth of trained and skilled professionals 80
5.3 RANGES/SCENARIOS 81
FIGURE 21 SPECTRUM OF SCENARIOS BASED ON IMPACT OF UNCERTAINTIES ON GROWTH OF STEM CELL ASSAYS MARKET 81
5.4 IMPACT OF COVID-19 ON STEM CELL ASSAYS MARKET 81
5.4.1 INTRODUCTION 81
5.4.2 RESEARCH & DEVELOPMENT 82
5.4.3 RESEARCH FUNDING 82
5.4.4 SUPPLY CHAIN 82
FIGURE 22 STEM CELL ASSAYS MARKET SCENARIO WITH AND WITHOUT
COVID-19 IMPACT, 2019-2021 83
5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESS 84
FIGURE 23 REVENUE SHIFT AND NEW REVENUE POCKETS FOR
STEM CELL ASSAY PRODUCT PROVIDERS 84
5.6 PRICING ANALYSIS 84
5.6.1 AVERAGE SELLING PRICE OF PRODUCTS OFFERED BY KEY PLAYERS 84
TABLE 3 AVERAGE SELLING PRICE OF PRODUCTS OFFERED BY KEY PLAYERS (TOP 5) 84
5.6.2 AVERAGE SELLING PRICE TREND 85
5.7 TECHNOLOGY ANALYSIS 85
5.7.1 MICROFABRICATION-ASSISTED TECHNOLOGIES 85
5.7.1.1 Microfluidics-based cell trap technology 85
5.7.1.2 Droplet-based microfluidic technology 86
5.7.1.3 Microwell-based analysis systems 86
5.7.2 ADVANCED TECHNOLOGIES 86
5.7.2.1 Bead-based multiplex assays 86
5.8 VALUE CHAIN ANALYSIS 86
FIGURE 24 VALUE CHAIN ANALYSIS OF STEM CELL ASSAYS MARKET 87
5.9 SUPPLY CHAIN ANALYSIS 88
FIGURE 25 STEM CELL ASSAYS MARKET: SUPPLY CHAIN ANALYSIS 89
5.10 ECOSYSTEM ANALYSIS 89
FIGURE 26 ECOSYSTEM ANALYSIS: STEM CELL ASSAYS MARKET 89
TABLE 4 SUPPLY CHAIN ECOSYSTEM 90
5.11 PATENT ANALYSIS 91
FIGURE 27 PATENT APPLICATIONS RELATED TO STEM CELL ASSAYS MARKET,
JANUARY 2012–MARCH 2022 91
5.12 KEY CONFERENCES AND EVENTS IN 2022–2023 92
TABLE 5 STEM CELL ASSAYS MARKET: LIST OF CONFERENCES AND EVENTS 92
5.13 REGULATORY ANALYSIS 94
5.13.1 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS IN DIFFERENT REGIONS/COUNTRIES 94
5.13.2 REGULATORY ANALYSIS FOR STEM CELL RESEARCH 95
5.13.2.1 US 95
5.13.2.2 EUROPE 95
5.13.2.2.1 Germany 95
5.13.2.2.2 UK 95
5.13.2.2.3 France 95
5.13.2.2.4 Italy 95
5.13.2.2.5 Spain 96
5.13.2.2.6 Switzerland 96
5.13.3 REGULATORY ANALYSIS FOR STEM CELL THERAPY 96
5.13.3.1 US 96
5.13.3.2 European Union 97
5.14 PORTER’S FIVE FORCES ANALYSIS 97
TABLE 6 STEM CELL ASSAYS MARKET: PORTER’S FIVE FORCES ANALYSIS 97
5.14.1 THREAT OF NEW ENTRANTS 98
5.14.2 THREAT OF SUBSTITUTES 98
5.14.3 BARGAINING POWER OF BUYERS 98
5.14.4 BARGAINING POWER OF SUPPLIERS 98
5.14.5 DEGREE OF COMPETITION 98
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA 99
5.15.1 KEY STAKEHOLDERS IN PHARMACEUTICAL COMPANIES
AND THEIR INFLUENCE IN BUYING PROCESS 99
FIGURE 28 INFLUENCE OF STAKEHOLDERS IN PHARMACEUTICAL
COMPANIES IN BUYING PROCESS OF STEM CELL ASSAY PRODUCTS 99
5.15.2 KEY BUYING CRITERIA FOR STEM CELL ASSAY PRODUCTS
AMONG END USERS 99
FIGURE 29 KEY BUYING CRITERIA FOR END USERS 99
6 STEM CELL ASSAYS MARKET, BY TYPE 100
6.1 INTRODUCTION 101
TABLE 7 STEM CELL ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION) 101
6.2 VIABILITY/CYTOTOXICITY ASSAYS 101
TABLE 8 VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY REGION,
2020–2027 (USD MILLION) 102
TABLE 9 NORTH AMERICA: VIABILITY/CYTOTOXICITY ASSAYS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 102
TABLE 10 EUROPE: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 102
TABLE 11 ASIA PACIFIC: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 103
TABLE 12 VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE,
2020–2027 (USD MILLION) 103
6.2.1 TETRAZOLIUM REDUCTION ASSAYS 103
6.2.1.1 Growing use of tetrazolium reduction assays in high-throughput screening to drive segment growth 103
TABLE 13 TETRAZOLIUM REDUCTION ASSAYS MARKET, BY REGION,
2020–2027 (USD MILLION) 104
TABLE 14 NORTH AMERICA: TETRAZOLIUM REDUCTION ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 104
TABLE 15 EUROPE: TETRAZOLIUM REDUCTION ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 104
TABLE 16 ASIA PACIFIC: TETRAZOLIUM REDUCTION ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 105
6.2.2 RESAZURIN CELL VIABILITY ASSAYS 105
6.2.2.1 Several advantages of resazurin cell viability assays to increase their adoption 105
TABLE 17 RESAZURIN CELL VIABILITY ASSAYS MARKET, BY REGION,
2020–2027 (USD MILLION) 105
TABLE 18 NORTH AMERICA: RESAZURIN CELL VIABILITY ASSAYS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 106
TABLE 19 EUROPE: RESAZURIN CELL VIABILITY ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 106
TABLE 20 ASIA PACIFIC: RESAZURIN CELL VIABILITY ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 106
6.2.3 CALCEIN-AM CELL VIABILITY ASSAYS 107
6.2.3.1 Wide applications of Calcein-AM cell viability assays across various assay techniques to drive segment growth 107
TABLE 21 CALCEIN-AM CELL VIABILITY ASSAYS MARKET, BY REGION,
2020–2027 (USD MILLION) 107
TABLE 22 NORTH AMERICA: CALCEIN-AM CELL VIABILITY ASSAYS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 107
TABLE 23 EUROPE: CALCEIN-AM CELL VIABILITY ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 108
TABLE 24 ASIA PACIFIC: CALCEIN-AM CELL VIABILITY ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 108
6.2.4 OTHER VIABILITY/CYTOTOXICITY ASSAYS 108
TABLE 25 OTHER VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY REGION,
2020–2027 (USD MILLION) 109
TABLE 26 NORTH AMERICA: OTHER VIABILITY/CYTOTOXICITY ASSAYS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 109
TABLE 27 EUROPE: OTHER VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 109
TABLE 28 ASIA PACIFIC: OTHER VIABILITY/CYTOTOXICITY ASSAYS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 110
6.3 ISOLATION & PURIFICATION ASSAYS 110
6.3.1 GROWING USE OF ISOLATION & PURIFICATION IN STEM CELL
ANALYSIS TO DRIVE SEGMENT GROWTH 110
TABLE 29 ISOLATION & PURIFICATION ASSAYS MARKET, BY REGION,
2020–2027 (USD MILLION) 110
TABLE 30 NORTH AMERICA: ISOLATION & PURIFICATION ASSAYS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 111
TABLE 31 EUROPE: ISOLATION & PURIFICATION ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 111
TABLE 32 ASIA PACIFIC: ISOLATION & PURIFICATION ASSAYS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 111
6.4 CELL IDENTIFICATION ASSAYS 112
6.4.1 CELL IDENTIFICATION ASSAYS IDENTIFY TARGET CELLS THROUGH MARKERS, BUFFERS, AND REAGENTS 112
TABLE 33 CELL IDENTIFICATION ASSAYS MARKET, BY REGION,
2020–2027 (USD MILLION) 112
TABLE 34 NORTH AMERICA: CELL IDENTIFICATION ASSAYS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 112
TABLE 35 EUROPE: CELL IDENTIFICATION ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 113
TABLE 36 ASIA PACIFIC: CELL IDENTIFICATION ASSAYS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 113
6.5 PROLIFERATION ASSAYS 114
6.5.1 CELL PROLIFERATION IS MEASURED ON THE BASIS OF
AVERAGE DNA CONTENT AND CELLULAR METABOLISM 114
TABLE 37 PROLIFERATION ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION) 114
TABLE 38 NORTH AMERICA: PROLIFERATION ASSAYS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 114
TABLE 39 EUROPE: PROLIFERATION ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 115
TABLE 40 ASIA PACIFIC: PROLIFERATION ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 115
6.6 DIFFERENTIATION ASSAYS 116
6.6.1 AVAILABILITY OF VARIOUS STEM CELL DIFFERENTIAL ASSAY KITS TO BOOST SEGMENT GROWTH 116
TABLE 41 DIFFERENTIATION ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION) 116
TABLE 42 NORTH AMERICA: DIFFERENTIATION ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 116
TABLE 43 EUROPE: DIFFERENTIATION ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 117
TABLE 44 ASIA PACIFIC: DIFFERENTIATION ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 117
6.7 FUNCTION ASSAYS 118
6.7.1 RISING DEMAND FOR FUNCTION ASSAYS IN DRUG DISCOVERY TO DRIVE SEGMENT GROWTH 118
TABLE 45 FUNCTION ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION) 118
TABLE 46 NORTH AMERICA: FUNCTION ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 118
TABLE 47 EUROPE: FUNCTION ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 119
TABLE 48 ASIA PACIFIC: FUNCTION ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 119
6.8 APOPTOSIS ASSAYS 120
TABLE 49 APOPTOSIS ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION) 120
TABLE 50 NORTH AMERICA: APOPTOSIS ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 120
TABLE 51 EUROPE: APOPTOSIS ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 121
TABLE 52 ASIA PACIFIC: APOPTOSIS ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 121
TABLE 53 APOPTOSIS ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION) 121
6.8.1 CASPASE ASSAYS 122
6.8.1.1 Advantages offered by caspase assays to drive segment growth 122
TABLE 54 CASPASE ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION) 122
TABLE 55 NORTH AMERICA: CASPASE ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 122
TABLE 56 EUROPE: CASPASE ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 123
TABLE 57 ASIA PACIFIC: CASPASE ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 123
6.8.2 ANNEXIN V & CELL PERMEABILITY ASSAYS 123
6.8.2.1 Increasing use of annexin V and cell permeability assays to drive segment growth 123
TABLE 58 ANNEXIN V & CELL PERMEABILITY ASSAYS MARKET, BY REGION,
2020–2027 (USD MILLION) 124
TABLE 59 NORTH AMERICA: ANNEXIN V & CELL PERMEABILITY ASSAYS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 124
TABLE 60 EUROPE: ANNEXIN V & CELL PERMEABILITY ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 124
TABLE 61 ASIA PACIFIC: ANNEXIN V & CELL PERMEABILITY ASSAYS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 125
6.8.3 DNA FRAGMENTATION ASSAYS 125
6.8.3.1 DNA fragmentation assays are used to study the
later stages of apoptosis 125
TABLE 62 DNA FRAGMENTATION ASSAYS MARKET, BY REGION,
2020–2027 (USD MILLION) 125
TABLE 63 NORTH AMERICA: DNA FRAGMENTATION ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 126
TABLE 64 EUROPE: DNA FRAGMENTATION ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 126
TABLE 65 ASIA PACIFIC: DNA FRAGMENTATION ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 126
6.8.4 MITOCHONDRIAL ASSAYS 127
6.8.4.1 Mitochondrial assays are widely used to detect mitochondrial changes associated with apoptosis 127
TABLE 66 MITOCHONDRIAL ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION) 127
TABLE 67 NORTH AMERICA: MITOCHONDRIAL ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 127
TABLE 68 EUROPE: MITOCHONDRIAL ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 128
TABLE 69 ASIA PACIFIC: MITOCHONDRIAL ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 128

7 STEM CELL ASSAYS MARKET, BY CELL TYPE 129
7.1 INTRODUCTION 130
TABLE 70 STEM CELL ASSAYS MARKET, BY CELL TYPE, 2020–2027 (USD MILLION) 130
7.2 ADULT STEM CELLS 130
TABLE 71 ADULT STEM CELL ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION) 130
TABLE 72 ADULT STEM CELLS ASSAYS MARKET, BY REGION,
2020–2027 (USD MILLION) 131
TABLE 73 NORTH AMERICA: ADULT STEM CELL ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 131
TABLE 74 EUROPE: ADULT STEM CELL ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 131
TABLE 75 ASIA PACIFIC: ADULT STEM CELL ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 132
7.2.1 MESENCHYMAL STEM CELLS 132
7.2.1.1 Increasing adoption of MSCs as potential treatment for various conditions to drive market growth 132
TABLE 76 MESENCHYMAL STEM CELL ASSAYS MARKET, BY REGION,
2020–2027 (USD MILLION) 133
TABLE 77 NORTH AMERICA: MESENCHYMAL STEM CELL ASSAYS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 133
TABLE 78 EUROPE: MESENCHYMAL STEM CELL ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 134
TABLE 79 ASIA PACIFIC: MESENCHYMAL STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 134
7.2.2 INDUCED PLURIPOTENT STEM CELLS 134
7.2.2.1 Increased adoption of iPSCs in research on cell therapies & regenerative medicine to support market growth 134
TABLE 80 INDUCED PLURIPOTENT STEM CELL ASSAYS MARKET, BY REGION,
2020–2027 (USD MILLION) 135
TABLE 81 NORTH AMERICA: INDUCED PLURIPOTENT STEM CELL ASSAYS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 135
TABLE 82 EUROPE: INDUCED PLURIPOTENT STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 136
TABLE 83 ASIA PACIFIC: INDUCED PLURIPOTENT STEM CELL ASSAYS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 136
7.2.3 HEMATOPOIETIC STEM CELLS 136
7.2.3.1 Increasing focus on developing HSC-based therapies to
drive market growth 136
TABLE 84 HEMATOPOIETIC STEM CELL ASSAYS MARKET, BY REGION,
2020–2027 (USD MILLION) 137
TABLE 85 NORTH AMERICA: HEMATOPOIETIC STEM CELL ASSAYS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 137
TABLE 86 EUROPE: HEMATOPOIETIC STEM CELL ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 138
TABLE 87 ASIA PACIFIC: HEMATOPOIETIC STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 138
7.2.4 UMBILICAL CORD STEM CELLS 138
7.2.4.1 Rising investments and collaborations for developing umbilical cord stem cell therapies to propel market growth 138
TABLE 88 UMBILICAL CORD STEM CELL ASSAYS MARKET, BY REGION,
2020–2027 (USD MILLION) 139
TABLE 89 NORTH AMERICA: UMBILICAL CORD STEM CELL ASSAYS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 139
TABLE 90 EUROPE: UMBILICAL CORD STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 140
TABLE 91 ASIA PACIFIC: UMBILICAL CORD STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 140
7.2.5 NEURAL STEM CELLS 140
7.2.5.1 Increasing research to evaluate the potency of NSCs in disease treatment will drive segment growth 140
TABLE 92 NEURAL STEM CELL ASSAYS MARKET, BY REGION,
2020–2027 (USD MILLION) 141
TABLE 93 NORTH AMERICA: NEURAL STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 141
TABLE 94 EUROPE: NEURAL STEM CELL ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 142
TABLE 95 ASIA PACIFIC: NEURAL STEM CELL ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 142
7.3 HUMAN EMBRYONIC STEM CELLS 142
7.3.1 ESCS CAN BE STORED AND PROCESSED EASILY 142
TABLE 96 HUMAN EMBRYONIC STEM CELL ASSAYS MARKET, BY REGION,
2020–2027 (USD MILLION) 143
TABLE 97 NORTH AMERICA: HUMAN EMBRYONIC STEM CELL ASSAYS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 143
TABLE 98 EUROPE: HUMAN EMBRYONIC STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 143
TABLE 99 ASIA PACIFIC: HUMAN EMBRYONIC STEM CELL ASSAYS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 144
8 STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE 145
8.1 INTRODUCTION 146
TABLE 100 STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION) 146
8.2 INSTRUMENTS 146
TABLE 101 STEM CELL ASSAY INSTRUMENTS MARKET, BY REGION,
2020–2027 (USD MILLION) 147
TABLE 102 NORTH AMERICA: STEM CELL ASSAY INSTRUMENTS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 147
TABLE 103 EUROPE: STEM CELL ASSAY INSTRUMENTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 147
TABLE 104 ASIA PACIFIC: STEM CELL ASSAY INSTRUMENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 148
TABLE 105 STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 148
8.2.1 FLOW CYTOMETERS 149
8.2.1.1 Technological advancements in flow cytometry
to drive segment growth 149
TABLE 106 FLOW CYTOMETERS MARKET, BY REGION, 2020–2027 (USD MILLION) 149
TABLE 107 NORTH AMERICA: FLOW CYTOMETERS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 150
TABLE 108 EUROPE: FLOW CYTOMETERS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 150
TABLE 109 ASIA PACIFIC: FLOW CYTOMETERS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 150
8.2.2 CELL IMAGING & ANALYSIS SYSTEMS 151
8.2.2.1 High demand for cell imaging and analysis in cell behavior research studies to support segment growth 151
TABLE 110 CELL IMAGING & ANALYSIS SYSTEMS MARKET, BY REGION,
2020–2027 (USD MILLION) 151
TABLE 111 NORTH AMERICA: CELL IMAGING & ANALYSIS SYSTEMS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 152
TABLE 112 EUROPE: CELL IMAGING & ANALYSIS SYSTEMS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 152
TABLE 113 ASIA PACIFIC: CELL IMAGING & ANALYSIS SYSTEMS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 152
8.2.3 MICROELECTRODE ARRAYS 153
8.2.3.1 Increasing use of microelectrode arrays in stem cell research
to drive segment growth 153
TABLE 114 MICROELECTRODE ARRAYS MARKET, BY REGION, 2020–2027 (USD MILLION) 153
TABLE 115 NORTH AMERICA: MICROELECTRODE ARRAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 154
TABLE 116 EUROPE: MICROELECTRODE ARRAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 154
TABLE 117 ASIA PACIFIC: MICROELECTRODE ARRAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 154
8.2.4 AUTOMATED CELL COUNTERS 155
8.2.4.1 Increasing adoption of automated cell counters to
drive segment growth 155
TABLE 118 AUTOMATED CELL COUNTERS MARKET, BY REGION,
2020–2027 (USD MILLION) 155
TABLE 119 NORTH AMERICA: AUTOMATED CELL COUNTERS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 155
TABLE 120 EUROPE: AUTOMATED CELL COUNTERS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 156
TABLE 121 ASIA PACIFIC: AUTOMATED CELL COUNTERS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 156
8.3 KITS 157
8.3.1 RAPID EVOLUTION OF ASSAY PLATFORMS AND EMERGENCE OF NEW TECHNOLOGY PLATFORMS TO DRIVE SEGMENT GROWTH 157
TABLE 122 STEM CELL ASSAY KITS MARKET, BY REGION, 2020–2027 (USD MILLION) 157
TABLE 123 NORTH AMERICA: STEM CELL ASSAY KITS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 157
TABLE 124 EUROPE: STEM CELL ASSAY KITS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 158
TABLE 125 ASIA PACIFIC: STEM CELL ASSAY KITS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 158
8.4 SERVICES 159
8.4.1 RISING DEMAND FOR ASSAY DEVELOPMENT SERVICES TO
DRIVE SEGMENT GROWTH 159
TABLE 126 STEM CELL ASSAY SERVICES MARKET, BY REGION,
2020–2027 (USD MILLION) 159
TABLE 127 NORTH AMERICA: STEM CELL ASSAY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 159
TABLE 128 EUROPE: STEM CELL ASSAY SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 160
TABLE 129 ASIA PACIFIC: STEM CELL ASSAY SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 160
9 STEM CELL ASSAYS MARKET, BY APPLICATION 161
9.1 INTRODUCTION 162
TABLE 130 STEM CELL ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 162
9.2 REGENERATIVE MEDICINE & THERAPY DEVELOPMENT 162
TABLE 131 STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY REGION, 2020–2027 (USD MILLION) 163
TABLE 132 NORTH AMERICA: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY COUNTRY,
2020–2027 (USD MILLION) 163
TABLE 133 EUROPE: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY COUNTRY, 2020–2027 (USD MILLION) 163
TABLE 134 ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY COUNTRY, 2020–2027 (USD MILLION) 164
TABLE 135 STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION) 164
9.2.1 ORTHOPEDIC, MUSCULOSKELETAL, AND SPINE APPLICATIONS 164
9.2.1.1 Increasing prevalence of orthopedic disorders to
drive segment growth 164
TABLE 136 STEM CELL ASSAYS MARKET FOR ORTHOPEDIC, MUSCULOSKELETAL, AND SPINE APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 165
TABLE 137 NORTH AMERICA: STEM CELL ASSAYS MARKET FOR ORTHOPEDIC, MUSCULOSKELETAL, AND SPINE APPLICATIONS, BY COUNTRY,
2020–2027 (USD MILLION) 165
TABLE 138 EUROPE: STEM CELL ASSAYS MARKET FOR ORTHOPEDIC, MUSCULOSKELETAL, AND SPINE APPLICATIONS, BY COUNTRY,
2020–2027 (USD MILLION) 166
TABLE 139 ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR ORTHOPEDIC, MUSCULOSKELETAL, AND SPINE APPLICATIONS, BY COUNTRY,
2020–2027 (USD MILLION) 166
9.2.2 DERMATOLOGY APPLICATIONS 167
9.2.2.1 Increasing use of stem cells in skin disease treatment to drive segment growth 167
TABLE 140 STEM CELL ASSAYS MARKET FOR DERMATOLOGY APPLICATIONS,
BY REGION, 2020–2027 (USD MILLION) 167
TABLE 141 NORTH AMERICA: STEM CELL ASSAYS MARKET FOR DERMATOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 167
TABLE 142 EUROPE: STEM CELL ASSAYS MARKET FOR DERMATOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 168
TABLE 143 ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR DERMATOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 168
9.2.3 CARDIOVASCULAR APPLICATIONS 169
9.2.3.1 Growing demand for effective cardiovascular disease treatments and rising number of R&D activities to drive segment growth 169
TABLE 144 STEM CELL ASSAYS MARKET FOR CARDIOVASCULAR APPLICATIONS,
BY REGION, 2020–2027 (USD MILLION) 169
TABLE 145 NORTH AMERICA: STEM CELL ASSAYS MARKET FOR CARDIOVASCULAR APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 170
TABLE 146 EUROPE: STEM CELL ASSAYS MARKET FOR CARDIOVASCULAR APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 170
TABLE 147 ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR CARDIOVASCULAR APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 170
9.2.4 CENTRAL NERVOUS SYSTEM APPLICATIONS 171
9.2.4.1 Promising stem cell therapies for degenerative neurological disorders to drive segment growth 171
TABLE 148 STEM CELL ASSAYS MARKET FOR CENTRAL NERVOUS SYSTEM APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 171
TABLE 149 NORTH AMERICA: STEM CELL ASSAYS MARKET FOR CENTRAL NERVOUS SYSTEM APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 171
TABLE 150 EUROPE: STEM CELL ASSAYS MARKET FOR CENTRAL NERVOUS SYSTEM APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 172
TABLE 151 ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR CENTRAL NERVOUS SYSTEM APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 172
9.2.5 ONCOLOGY APPLICATIONS 173
9.2.5.1 Increasing prevalence of cancer to drive segment growth 173
TABLE 152 INCREASING INCIDENCE OF CANCER, BY REGION,
2020 VS. 2030 VS. 2040 (MILLION) 173
TABLE 153 PROJECTED INCREASE IN THE GLOBAL NUMBER OF CANCER PATIENTS, 2015–2035 173
TABLE 154 STEM CELL ASSAYS MARKET FOR ONCOLOGY APPLICATIONS,
BY REGION, 2020–2027 (USD MILLION) 174
TABLE 155 NORTH AMERICA: STEM CELL ASSAYS MARKET FOR ONCOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 174
TABLE 156 EUROPE: STEM CELL ASSAYS MARKET FOR ONCOLOGY APPLICATIONS,
BY COUNTRY, 2020–2027 (USD MILLION) 174
TABLE 157 ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR ONCOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 175
9.2.6 DIABETES APPLICATIONS 175
9.2.6.1 Rising incidence of diabetes to drive segment growth 175
TABLE 158 TOP FIVE COUNTRIES WITH THE HIGHEST NUMBER OF
DIABETICS (20–79 YEARS), 2021 VS. 2045 175
TABLE 159 STEM CELL ASSAYS MARKET FOR DIABETES APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 176
TABLE 160 NORTH AMERICA: STEM CELL ASSAYS MARKET FOR DIABETES APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 176
TABLE 161 EUROPE: STEM CELL ASSAYS MARKET FOR DIABETES APPLICATIONS,
BY COUNTRY, 2020–2027 (USD MILLION) 177
TABLE 162 ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR DIABETES APPLICATIONS,
BY COUNTRY, 2020–2027 (USD MILLION) 177
9.2.7 OTHER REGENERATIVE MEDICINE & THERAPY DEVELOPMENT APPLICATIONS 178
TABLE 163 STEM CELL ASSAYS MARKET FOR OTHER REGENERATIVE MEDICINE & THERAPY DEVELOPMENT APPLICATIONS, BY REGION,
2020–2027 (USD MILLION) 178
TABLE 164 NORTH AMERICA: STEM CELL ASSAYS MARKET FOR OTHER REGENERATIVE MEDICINE & THERAPY DEVELOPMENT APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 178
TABLE 165 EUROPE: STEM CELL ASSAYS MARKET FOR OTHER REGENERATIVE
MEDICINE & THERAPY DEVELOPMENT APPLICATIONS, BY COUNTRY,
2020–2027 (USD MILLION) 179
TABLE 166 ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR OTHER REGENERATIVE MEDICINE & THERAPY DEVELOPMENT APPLICATIONS, BY COUNTRY,
2020–2027 (USD MILLION) 179
9.3 DRUG DISCOVERY & DEVELOPMENT 180
9.3.1 RECENT PROGRESS IN THE DEVELOPMENT OF STEM CELL ASSAYS
TO DRIVE SEGMENT GROWTH 180
TABLE 167 STEM CELL ASSAYS MARKET FOR DRUG DISCOVERY & DEVELOPMENT,
BY REGION, 2020–2027 (USD MILLION) 180
TABLE 168 NORTH AMERICA: STEM CELL ASSAYS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2020–2027 (USD MILLION) 181
TABLE 169 EUROPE: STEM CELL ASSAYS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2020–2027 (USD MILLION) 181
TABLE 170 ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2020–2027 (USD MILLION) 181
9.4 CLINICAL RESEARCH 182
9.4.1 INCREASING NUMBER OF PROMISING CLINICAL TRIALS USING
STEM CELLS TO BOOST SEGMENT GROWTH 182
TABLE 171 STEM CELL ASSAYS MARKET FOR CLINICAL RESEARCH, BY REGION,
2020–2027 (USD MILLION) 182
TABLE 172 NORTH AMERICA: STEM CELL ASSAYS MARKET FOR CLINICAL RESEARCH,
BY COUNTRY, 2020–2027 (USD MILLION) 182
TABLE 173 EUROPE: STEM CELL ASSAYS MARKET FOR CLINICAL RESEARCH,
BY COUNTRY, 2020–2027 (USD MILLION) 183
TABLE 174 ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR CLINICAL RESEARCH,
BY COUNTRY, 2020–2027 (USD MILLION) 183

10 STEM CELL ASSAYS MARKET, BY END USER 184
10.1 INTRODUCTION 185
TABLE 175 STEM CELL ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION) 185
10.2 BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 185
10.2.1 BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES ARE LARGEST END USERS OF STEM CELL ASSAYS 185
TABLE 176 STEM CELL ASSAYS MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2020–2027 (USD MILLION) 186
TABLE 177 NORTH AMERICA: STEM CELL ASSAYS MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 186
TABLE 178 EUROPE: STEM CELL ASSAYS MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 187
TABLE 179 ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 187
10.3 ACADEMIC & RESEARCH INSTITUTES 188
10.3.1 NEW STEM CELL RESEARCH INSTITUTES ARE BEING ESTABLISHED FOR STEM CELL RESEARCH AND REGENERATIVE MEDICINE 188
TABLE 180 STEM CELL ASSAYS MARKET FOR ACADEMIC & RESEARCH INSTITUTES,
BY REGION, 2020–2027 (USD MILLION) 188
TABLE 181 NORTH AMERICA: STEM CELL ASSAYS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION) 189
TABLE 182 EUROPE: STEM CELL ASSAYS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION) 189
TABLE 183 ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION) 189
11 STEM CELL ASSAYS MARKET, BY REGION 190
11.1 INTRODUCTION 191
TABLE 184 STEM CELL ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION) 191
11.2 NORTH AMERICA 191
FIGURE 30 NORTH AMERICA: STEM CELL ASSAYS MARKET SNAPSHOT 192
TABLE 185 NORTH AMERICA: STEM CELL ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 193
TABLE 186 NORTH AMERICA: STEM CELL ASSAYS MARKET, BY TYPE,
2020–2027 (USD MILLION) 193
TABLE 187 NORTH AMERICA: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE,
2020–2027 (USD MILLION) 193
TABLE 188 NORTH AMERICA: APOPTOSIS ASSAYS MARKET, BY TYPE,
2020–2027 (USD MILLION) 194
TABLE 189 NORTH AMERICA: STEM CELL ASSAYS MARKET, BY CELL TYPE,
2020–2027 (USD MILLION) 194
TABLE 190 NORTH AMERICA: ADULT STEM CELLS MARKET, BY TYPE,
2020–2027 (USD MILLION) 194
TABLE 191 NORTH AMERICA: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 195
TABLE 192 NORTH AMERICA: STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 195
TABLE 193 NORTH AMERICA: STEM CELL ASSAYS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 195
TABLE 194 NORTH AMERICA: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION) 196
TABLE 195 NORTH AMERICA: STEM CELL ASSAYS MARKET, BY END USER,
2020–2027 (USD MILLION) 196
11.2.1 US 196
11.2.1.1 Rising funding for stem cell research to drive market growth 196
TABLE 196 US: STEM CELL ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION) 197
TABLE 197 US: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE,
2020–2027 (USD MILLION) 197
TABLE 198 US: APOPTOSIS ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION) 198
TABLE 199 US: STEM CELL ASSAYS MARKET, BY CELL TYPE, 2020–2027 (USD MILLION) 198
TABLE 200 US: ADULT STEM CELLS MARKET, BY TYPE, 2020–2027 (USD MILLION) 198
TABLE 201 US: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION) 199
TABLE 202 US: STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 199
TABLE 203 US: STEM CELL ASSAYS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 199
TABLE 204 US: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION) 200
TABLE 205 US: STEM CELL ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION) 200
11.2.2 CANADA 200
11.2.2.1 Rising government investments & funding to drive market in Canada 200
TABLE 206 CANADA: STEM CELL ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION) 201
TABLE 207 CANADA: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE,
2020–2027 (USD MILLION) 202
TABLE 208 CANADA: APOPTOSIS ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION) 202
TABLE 209 CANADA: STEM CELL ASSAYS MARKET, BY CELL TYPE,
2020–2027 (USD MILLION) 202
TABLE 210 CANADA: ADULT STEM CELLS MARKET, BY TYPE, 2020–2027 (USD MILLION) 203
TABLE 211 CANADA: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION) 203
TABLE 212 CANADA: STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 203
TABLE 213 CANADA: STEM CELL ASSAYS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 204
TABLE 214 CANADA: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION) 204
TABLE 215 CANADA: STEM CELL ASSAYS MARKET, BY END USER,
2020–2027 (USD MILLION) 204

11.3 EUROPE 205
TABLE 216 EUROPE: STEM CELL ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 205
TABLE 217 EUROPE: STEM CELL ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION) 205
TABLE 218 EUROPE: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE,
2020–2027 (USD MILLION) 206
TABLE 219 EUROPE: APOPTOSIS ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION) 206
TABLE 220 EUROPE: STEM CELL ASSAYS MARKET, BY CELL TYPE,
2020–2027 (USD MILLION) 206
TABLE 221 EUROPE: ADULT STEM CELLS MARKET, BY TYPE, 2020–2027 (USD MILLION) 207
TABLE 222 EUROPE: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION) 207
TABLE 223 EUROPE: STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 207
TABLE 224 EUROPE: STEM CELL ASSAYS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 208
TABLE 225 EUROPE: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION) 208
TABLE 226 EUROPE: STEM CELL ASSAYS MARKET, BY END USER,
2020–2027 (USD MILLION) 208
11.3.1 GERMANY 209
11.3.1.1 Growing biopharma industry and focus on regenerative medicine to drive market growth 209
TABLE 227 GERMANY: STEM CELL ASSAYS MARKET, BY TYPE,
2020–2027 (USD MILLION) 209
TABLE 228 GERMANY: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE,
2020–2027 (USD MILLION) 210
TABLE 229 GERMANY: APOPTOSIS ASSAYS MARKET, BY TYPE,
2020–2027 (USD MILLION) 210
TABLE 230 GERMANY: STEM CELL ASSAYS MARKET, BY CELL TYPE,
2020–2027 (USD MILLION) 210
TABLE 231 GERMANY: ADULT STEM CELLS MARKET, BY TYPE,
2020–2027 (USD MILLION) 211
TABLE 232 GERMANY: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION) 211
TABLE 233 GERMANY: STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 211
TABLE 234 GERMANY: STEM CELL ASSAYS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 212
TABLE 235 GERMANY: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION) 212
TABLE 236 GERMANY: STEM CELL ASSAYS MARKET, BY END USER,
2020–2027 (USD MILLION) 212
11.3.2 UK 213
11.3.2.1 Focus on innovation will increase demand for stem cell-based therapeutics 213
TABLE 237 UK: STEM CELL ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION) 213
TABLE 238 UK: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE,
2020–2027 (USD MILLION) 214
TABLE 239 UK: APOPTOSIS ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION) 214
TABLE 240 UK: STEM CELL ASSAYS MARKET, BY CELL TYPE, 2020–2027 (USD MILLION) 214
TABLE 241 UK: ADULT STEM CELLS MARKET, BY TYPE, 2020–2027 (USD MILLION) 215
TABLE 242 UK: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION) 215
TABLE 243 UK: STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 215
TABLE 244 UK: STEM CELL ASSAYS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 216
TABLE 245 UK: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION) 216
TABLE 246 UK: STEM CELL ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION) 216
11.3.3 FRANCE 217
11.3.3.1 Government initiatives to support market growth in France 217
TABLE 247 FRANCE: STEM CELL ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION) 217
TABLE 248 FRANCE: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE,
2020–2027 (USD MILLION) 218
TABLE 249 FRANCE: APOPTOSIS ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION) 218
TABLE 250 FRANCE: STEM CELL ASSAYS MARKET, BY CELL TYPE,
2020–2027 (USD MILLION) 218
TABLE 251 FRANCE: ADULT STEM CELLS MARKET, BY TYPE, 2020–2027 (USD MILLION) 219
TABLE 252 FRANCE: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION) 219
TABLE 253 FRANCE: STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 219
TABLE 254 FRANCE: STEM CELL ASSAYS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 220
TABLE 255 FRANCE: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION) 220
TABLE 256 FRANCE: STEM CELL ASSAYS MARKET, BY END USER,
2020–2027 (USD MILLION) 220
11.3.4 ITALY 221
11.3.4.1 Investment in R&D for development of new therapeutics to boost stem cell assays market 221
TABLE 257 ITALY: STEM CELL ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION) 221
TABLE 258 ITALY: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE,
2020–2027 (USD MILLION) 222
TABLE 259 ITALY: APOPTOSIS ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION) 222
TABLE 260 ITALY: STEM CELL ASSAYS MARKET, BY CELL TYPE,
2020–2027 (USD MILLION) 222
TABLE 261 ITALY: ADULT STEM CELLS MARKET, BY TYPE, 2020–2027 (USD MILLION) 223
TABLE 262 ITALY: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION) 223
TABLE 263 ITALY: STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 223
TABLE 264 ITALY: STEM CELL ASSAYS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 224
TABLE 265 ITALY: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION) 224
TABLE 266 ITALY: STEM CELL ASSAYS MARKET, BY END USER,
2020–2027 (USD MILLION) 224
11.3.5 SPAIN 225
11.3.5.1 Increasing investments from private and public organizations to drive market growth 225
TABLE 267 SPAIN: STEM CELL ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION) 225
TABLE 268 SPAIN: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE,
2020–2027 (USD MILLION) 225
TABLE 269 SPAIN: APOPTOSIS ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION) 226
TABLE 270 SPAIN: STEM CELL ASSAYS MARKET, BY CELL TYPE,
2020–2027 (USD MILLION) 226
TABLE 271 SPAIN: ADULT STEM CELLS MARKET, BY TYPE, 2020–2027 (USD MILLION) 226
TABLE 272 SPAIN: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION) 227
TABLE 273 SPAIN: STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 227
TABLE 274 SPAIN: STEM CELL ASSAYS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 227
TABLE 275 SPAIN: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION) 228
TABLE 276 SPAIN: STEM CELL ASSAYS MARKET, BY END USER,
2020–2027 (USD MILLION) 228
11.3.6 SWITZERLAND 229
11.3.6.1 Growing life science research to drive market growth 229
TABLE 277 SWITZERLAND: STEM CELL ASSAYS MARKET, BY TYPE,
2020–2027 (USD MILLION) 229
TABLE 278 SWITZERLAND: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE,
2020–2027 (USD MILLION) 229
TABLE 279 SWITZERLAND: APOPTOSIS ASSAYS MARKET, BY TYPE,
2020–2027 (USD MILLION) 230
TABLE 280 SWITZERLAND: STEM CELL ASSAYS MARKET, BY CELL TYPE,
2020–2027 (USD MILLION) 230
TABLE 281 SWITZERLAND: ADULT STEM CELLS MARKET, BY TYPE,
2020–2027 (USD MILLION) 230
TABLE 282 SWITZERLAND: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 231
TABLE 283 SWITZERLAND: STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 231
TABLE 284 SWITZERLAND: STEM CELL ASSAYS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 231
TABLE 285 SWITZERLAND: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION) 232
TABLE 286 SWITZERLAND: STEM CELL ASSAYS MARKET, BY END USER,
2020–2027 (USD MILLION) 232
11.3.7 REST OF EUROPE 232
TABLE 287 REST OF EUROPE: STEM CELL ASSAYS MARKET, BY TYPE,
2020–2027 (USD MILLION) 233
TABLE 288 REST OF EUROPE: VIABILITY/CYTOTOXICITY ASSAYS MARKET,
BY TYPE, 2020–2027 (USD MILLION) 233
TABLE 289 REST OF EUROPE: APOPTOSIS ASSAYS MARKET, BY TYPE,
2020–2027 (USD MILLION) 234
TABLE 290 REST OF EUROPE: STEM CELL ASSAYS MARKET, BY CELL TYPE,
2020–2027 (USD MILLION) 234
TABLE 291 REST OF EUROPE: ADULT STEM CELLS MARKET, BY TYPE,
2020–2027 (USD MILLION) 234
TABLE 292 REST OF EUROPE: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 235
TABLE 293 REST OF EUROPE: STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 235
TABLE 294 REST OF EUROPE: STEM CELL ASSAYS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 235
TABLE 295 REST OF EUROPE: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION) 236
TABLE 296 REST OF EUROPE: STEM CELL ASSAYS MARKET, BY END USER,
2020–2027 (USD MILLION) 236
11.4 ASIA PACIFIC 236
FIGURE 31 ASIA PACIFIC: STEM CELL ASSAYS MARKET SNAPSHOT 237
TABLE 297 ASIA PACIFIC: STEM CELL ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 238
TABLE 298 ASIA PACIFIC: STEM CELL ASSAYS MARKET, BY TYPE,
2020–2027 (USD MILLION) 238
TABLE 299 ASIA PACIFIC: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE,
2020–2027 (USD MILLION) 238
TABLE 300 ASIA PACIFIC: APOPTOSIS ASSAYS MARKET, BY TYPE,
2020–2027 (USD MILLION) 239
TABLE 301 ASIA PACIFIC: STEM CELL ASSAYS MARKET, BY CELL TYPE,
2020–2027 (USD MILLION) 239
TABLE 302 ASIA PACIFIC: ADULT STEM CELLS MARKET, BY TYPE,
2020–2027 (USD MILLION) 239
TABLE 303 ASIA PACIFIC: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION) 240
TABLE 304 ASIA PACIFIC: STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 240
TABLE 305 ASIA PACIFIC: STEM CELL ASSAYS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 240
TABLE 306 ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION) 241
TABLE 307 ASIA PACIFIC: STEM CELL ASSAYS MARKET, BY END USER,
2020–2027 (USD MILLION) 241
11.4.1 CHINA 241
11.4.1.1 Growing focus on stem cell research to drive market growth in China 241
TABLE 308 CHINA: STEM CELL ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION) 242
TABLE 309 CHINA: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE,
2020–2027 (USD MILLION) 243
TABLE 310 CHINA: APOPTOSIS ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION) 243
TABLE 311 CHINA: STEM CELL ASSAYS MARKET, BY CELL TYPE,
2020–2027 (USD MILLION) 243
TABLE 312 CHINA: ADULT STEM CELLS MARKET, BY TYPE, 2020–2027 (USD MILLION) 244
TABLE 313 CHINA: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION) 244
TABLE 314 CHINA: STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 244
TABLE 315 CHINA: STEM CELL ASSAYS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 245
TABLE 316 CHINA: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION) 245
TABLE 317 CHINA: STEM CELL ASSAYS MARKET, BY END USER,
2020–2027 (USD MILLION) 245
11.4.2 JAPAN 246
11.4.2.1 Growing collaborations for stem cell research to drive market growth in the country 246
TABLE 318 JAPAN: STEM CELL ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION) 246
TABLE 319 JAPAN: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE,
2020–2027 (USD MILLION) 247
TABLE 320 JAPAN: APOPTOSIS ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION) 247
TABLE 321 JAPAN: STEM CELL ASSAYS MARKET, BY CELL TYPE,
2020–2027 (USD MILLION) 247
TABLE 322 JAPAN: ADULT STEM CELLS MARKET, BY TYPE, 2020–2027 (USD MILLION) 248
TABLE 323 JAPAN: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION) 248
TABLE 324 JAPAN: STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 248
TABLE 325 JAPAN: STEM CELL ASSAYS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 249
TABLE 326 JAPAN: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION) 249
TABLE 327 JAPAN: STEM CELL ASSAYS MARKET, BY END USER,
2020–2027 (USD MILLION) 249
11.4.3 INDIA 250
11.4.3.1 Government initiatives supporting stem cell research to drive market growth in India 250
TABLE 328 INDIA: STEM CELL ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION) 250
TABLE 329 INDIA: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE,
2020–2027 (USD MILLION) 251
TABLE 330 INDIA: APOPTOSIS ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION) 251
TABLE 331 INDIA: STEM CELL ASSAYS MARKET, BY CELL TYPE,
2020–2027 (USD MILLION) 251
TABLE 332 INDIA: ADULT STEM CELLS MARKET, BY TYPE, 2020–2027 (USD MILLION) 252
TABLE 333 INDIA: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION) 252
TABLE 334 INDIA: STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 252
TABLE 335 INDIA: STEM CELL ASSAYS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 253
TABLE 336 INDIA: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION) 253
TABLE 337 INDIA: STEM CELL ASSAYS MARKET, BY END USER,
2020–2027 (USD MILLION) 253
11.4.4 REST OF ASIA PACIFIC 254
TABLE 338 REST OF ASIA PACIFIC: STEM CELL ASSAYS MARKET, BY TYPE,
2020–2027 (USD MILLION) 254
TABLE 339 REST OF ASIA PACIFIC: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION) 255
TABLE 340 REST OF ASIA PACIFIC: APOPTOSIS ASSAYS MARKET, BY TYPE,
2020–2027 (USD MILLION) 255
TABLE 341 REST OF ASIA PACIFIC: STEM CELL ASSAYS MARKET, BY CELL TYPE,
2020–2027 (USD MILLION) 255
TABLE 342 REST OF ASIA PACIFIC: ADULT STEM CELLS MARKET, BY TYPE,
2020–2027 (USD MILLION) 256
TABLE 343 REST OF ASIA PACIFIC: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 256
TABLE 344 REST OF ASIA PACIFIC: STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 256
TABLE 345 REST OF ASIA PACIFIC: STEM CELL ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 257
TABLE 346 REST OF ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION) 257
TABLE 347 REST OF ASIA PACIFIC: STEM CELL ASSAYS MARKET, BY END USER,
2020–2027 (USD MILLION) 257
11.5 LATIN AMERICA 258
11.5.1 GROWTH OF BIOPHARMACEUTICAL INDUSTRY TO DRIVE MARKET GROWTH IN LATIN AMERICA 258
TABLE 348 MEXICO: CANCER CASES, BY CANCER TYPE, 2020 258
TABLE 349 LATIN AMERICA: STEM CELL ASSAYS MARKET, BY TYPE,
2020–2027 (USD MILLION) 258
TABLE 350 LATIN AMERICA: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE,
2020–2027 (USD MILLION) 259
TABLE 351 LATIN AMERICA: APOPTOSIS ASSAYS MARKET, BY TYPE,
2020–2027 (USD MILLION) 259
TABLE 352 LATIN AMERICA: STEM CELL ASSAYS MARKET, BY CELL TYPE,
2020–2027 (USD MILLION) 259
TABLE 353 LATIN AMERICA: ADULT STEM CELLS MARKET, BY TYPE,
2020–2027 (USD MILLION) 260
TABLE 354 LATIN AMERICA: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 260
TABLE 355 LATIN AMERICA: STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 260
TABLE 356 LATIN AMERICA: STEM CELL ASSAYS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 261
TABLE 357 LATIN AMERICA: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION) 261
TABLE 358 LATIN AMERICA: STEM CELL ASSAYS MARKET, BY END USER,
2020–2027 (USD MILLION) 261
11.6 MIDDLE EAST & AFRICA 262
11.6.1 INCREASING COLLABORATIONS FOR STEM CELL RESEARCH TO DRIVE MARKET GROWTH IN MEA 262
TABLE 359 MIDDLE EAST & AFRICA: STEM CELL ASSAYS MARKET, BY TYPE,
2020–2027 (USD MILLION) 262
TABLE 360 MIDDLE EAST & AFRICA: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION) 263
TABLE 361 MIDDLE EAST & AFRICA: APOPTOSIS ASSAYS MARKET, BY TYPE,
2020–2027 (USD MILLION) 263
TABLE 362 MIDDLE EAST & AFRICA: STEM CELL ASSAYS MARKET, BY CELL TYPE,
2020–2027 (USD MILLION) 263
TABLE 363 MIDDLE EAST & AFRICA: ADULT STEM CELLS MARKET, BY TYPE,
2020–2027 (USD MILLION) 264
TABLE 364 MIDDLE EAST & AFRICA: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 264
TABLE 365 MIDDLE EAST & AFRICA: STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 264
TABLE 366 MIDDLE EAST & AFRICA: STEM CELL ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 265
TABLE 367 MIDDLE EAST & AFRICA: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION) 265
TABLE 368 MIDDLE EAST & AFRICA: STEM CELL ASSAYS MARKET, BY END USER,
2020–2027 (USD MILLION) 265
12 COMPETITIVE LANDSCAPE 266
12.1 INTRODUCTION 266
12.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS 267
FIGURE 32 STEM CELL ASSAYS MARKET: STRATEGIES ADOPTED 267
12.3 MARKET SHARE ANALYSIS 268
FIGURE 33 STEM CELL ASSAYS MARKET SHARE ANALYSIS, BY KEY PLAYER (2021) 268
TABLE 369 STEM CELL ASSAYS MARKET: DEGREE OF COMPETITION 268
12.4 REVENUE ANALYSIS 269
FIGURE 34 REVENUE ANALYSIS FOR KEY COMPANIES (2019-2021) 269
12.5 COMPANY EVALUATION QUADRANT 270
FIGURE 35 STEM CELL ASSAYS MARKET: COMPANY EVALUATION MATRIX, 2021 270
12.5.1 STARS 271
12.5.2 EMERGING LEADERS 271
12.5.3 PERVASIVE PLAYERS 271
12.5.4 PARTICIPANTS 271
12.6 COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS 271
12.6.1 OVERALL FOOTPRINT OF COMPANIES (25 COMPANIES) 271
TABLE 370 PRODUCT & REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN
STEM CELL ASSAYS MARKET 271
12.6.2 PRODUCT & SERVICE FOOTPRINT OF COMPANIES (25 COMPANIES) 273
TABLE 371 PRODUCT & SERVICE FOOTPRINT ANALYSIS OF KEY PLAYERS IN
STEM CELL ASSAYS MARKET 273
12.6.3 REGIONAL FOOTPRINT OF COMPANIES (25 COMPANIES) 274
TABLE 372 REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN
STEM CELL ASSAYS MARKET 274
12.7 COMPANY EVALUATION QUADRANT: STARTUPS/SMES 275
FIGURE 36 STEM CELL ASSAYS MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES, 2021 275
12.7.1 PROGRESSIVE COMPANIES 276
12.7.2 STARTING BLOCKS 276
12.7.3 RESPONSIVE COMPANIES 276
12.7.4 DYNAMIC COMPANIES 276
12.7.4.1 COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS 277
TABLE 373 STEM CELL ASSAYS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 277
TABLE 374 STEM CELL ASSAYS MARKET: COMPETITIVE BENCHMARKING
OF KEY PLAYERS (STARTUPS/SMES) 278
12.8 COMPETITIVE SCENARIO AND TRENDS 279
12.8.1 PRODUCT LAUNCHES 279
TABLE 375 STEM CELL ASSAYS MARKET: PRODUCT LAUNCHES,
JANUARY 2018-MAY 2022 279
12.8.2 DEALS 280
TABLE 376 STEM CELL ASSAYS MARKET: DEALS, JANUARY 2018-MAY 2022 280
12.8.3 OTHER DEVELOPMENTS 281
TABLE 377 STEM CELL ASSAYS MARKET: OTHER DEVELOPMENTS,
JANUARY 2018-MAY 2022 281
13 COMPANY PROFILES 282
13.1 KEY PLAYERS 282
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
13.1.1 THERMO FISHER SCIENTIFIC INC. 282
TABLE 378 THERMO FISHER SCIENTIFIC INC: BUSINESS OVERVIEW 282
FIGURE 37 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2021) 283
13.1.2 MERK KGAA 287
TABLE 379 MERCK KGAA: BUSINESS OVERVIEW 287
FIGURE 38 MERCK KGAA: COMPANY SNAPSHOT (2021) 288
13.1.3 DANAHER 292
TABLE 380 DANAHER: BUSINESS OVERVIEW 292
FIGURE 39 DANAHER: COMPANY SNAPSHOT (2021) 293
13.1.4 BECTON, DICKINSON AND COMPANY 297
TABLE 381 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW 297
FIGURE 40 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2021) 298
13.1.5 BIO-RAD LABORATORIES 300
TABLE 382 BIO-RAD LABORATORIES: BUSINESS OVERVIEW 300
FIGURE 41 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2021) 301
13.1.6 PERKINELMER INC. 303
TABLE 383 PERKINELMER INC.: BUSINESS OVERVIEW 303
FIGURE 42 PERKINELMER INC.: COMPANY SNAPSHOT (2021) 304
13.1.7 AGILENT TECHNOLOGIES, INC. 306
TABLE 384 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW 306
FIGURE 43 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2021) 307
13.1.8 BIO-TECHNE CORPORATION 309
TABLE 385 BIO-TECHNE CORPORATION: BUSINESS OVERVIEW 309
FIGURE 44 BIO-TECHNE CORPORATION: COMPANY SNAPSHOT (2020) 310
13.1.9 FUJIFILM HOLDINGS CORPORATION 312
TABLE 386 FUJIFILM HOLDINGS CORPORATION: BUSINESS OVERVIEW 312
FIGURE 45 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2020) 313
13.1.10 CHARLES RIVER LABORATORIES 315
TABLE 387 CHARLES RIVER LABORATORIES: BUSINESS OVERVIEW 315
FIGURE 46 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2021) 316
13.1.11 LONZA GROUP 318
TABLE 388 LONZA GROUP: BUSINESS OVERVIEW 318
FIGURE 47 LONZA GROUP: COMPANY SNAPSHOT (2021) 319
13.1.12 PROMEGA CORPORATION 321
TABLE 389 PROMEGA CORPORATION: BUSINESS OVERVIEW 321
13.1.13 MILTENYI BIOTEC 325
TABLE 390 MILTENYI BIOTEC: BUSINESS OVERVIEW 325
13.1.14 STEMCELL TECHNOLOGIES 327
TABLE 391 STEMCELL TECHNOLOGIES: BUSINESS OVERVIEW 327
13.1.15 HEMOGENIX INC. 330
TABLE 392 HEMOGENIX INC.: BUSINESS OVERVIEW 330
13.1.16 CELL BIOLABS, INC. 331
TABLE 393 CELL BIOLABS, INC.: BUSINESS OVERVIEW 331
13.2 OTHER COMPANIES 332
13.2.1 TAKARA BIO INC. 332
13.2.2 CREATIVE BIOARRAY 333
13.2.3 AAT BIOQUEST, INC. 334
13.2.4 ABCAM PLC 335
13.2.5 BPS BIOSCIENCE, INC. 336
13.2.6 ENZO BIOCHEM INC. 337
13.2.7 PROMOCELL GMBH 338
13.2.8 BIOTIUM 338
13.2.9 GENO TECHNOLOGY INC. 339
13.2.10 REACHBIO RESEARCH LABS 339
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

14 APPENDIX 340
14.1 DISCUSSION GUIDE 340
14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 344
14.3 AVAILABLE CUSTOMIZATIONS 346
14.4 RELATED REPORTS 346
14.5 AUTHOR DETAILS 347

★調査レポート[幹細胞アッセイのグローバル市場予測（～2027）：生存率、増殖、分化、アポトーシス] ( Stem Cell Assays Market by Type (Viability, Proliferation, Differentiation, Apoptosis), Cell Type (Mesenchymal, iPSCs, HSCs, hESCs), Product & Service (Instrument), Application (Regenerative Medicine, Clinical Research), End User - Global Forecast to 2027 / BT4628-22) 販売に関する免責事項

[幹細胞アッセイのグローバル市場予測（～2027）：生存率、増殖、分化、アポトーシス] ( Stem Cell Assays Market by Type (Viability, Proliferation, Differentiation, Apoptosis), Cell Type (Mesenchymal, iPSCs, HSCs, hESCs), Product & Service (Instrument), Application (Regenerative Medicine, Clinical Research), End User - Global Forecast to 2027 / BT4628-22) についてEメールでお問い合わせ

◆関連調査資料◆

ATPアッセイの世界市場予測（～2027）：製品別、用途別、エンドユーザー別
AST7417-22 / MarketsandMarkets / 2022年4月7日 / マーケッツアンドマーケッツ社は、世界のATPアッセイ市場規模が2022年276百万ドルから2027年412百万ドルまで、年平均8.4％成長すると予想しています。本市場調査資料では、ATPアッセイの世界市場を広く調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、製品別（消耗品・付属品、機器）分析、用途別（汚染検査、疾病検査、創薬・開発）分析、エンドユーザー別（製薬・バイオテクノロジー企業、食品・飲料産業、病院・診断研究機関、学術・研究機関）分析、地域別分析、競争状況、企業情報などの項目を掲載しています。・イントロダクション・調査手法・エグゼクティブサマリー・プレミアムインサイト・市場概要・世界のATPアッセイ市場規模：製品別（消耗品・付属品、機器）・世界のATPアッセイ市場規模：用途別（汚染検査、疾病検査、創薬・開発）・世界のATPアッセイ市場規模：エンドユーザー別（製薬・バイオテクノロジー企業、食品・飲料産業、病院・診断研究機関、学術・研究機関）・世界のATPアッセイ市場規模：地域別...“The global ATP assays market is projected to reach USD 412 million by 2027 from USD 276 million in 2022, at a CAGR of 8.4%.” The growth of this market can largely be attributed to the increasing food safety concerns, growing demand for ATP assays in pharmaceutical & biotechnology companies, rising investments in pharmaceutical & biotechnology R&D, increasing prevalence of cancer and other chronic and infectious diseases, and the shift from culture-based tests to rapid tests. However, the high cost of instruments and inability to differentiate between extracellular and intracellular ATP are expected to restrain the growth of this market...

タンジェンシャルフローろ過（TFF）の世界市場予測（～2027）：製品別、材料別、技術別、用途別、エンドユーザー別、地域別
BT4615-22 / MarketsandMarkets / 2022年4月25日 / マーケッツアンドマーケッツ社は、世界のタンジェンシャルフローろ過（TFF）市場規模が2022年15億ドルから2027年28億ドルまで、年平均13.2％成長すると予想しています。本市場調査資料では、タンジェンシャルフローろ過（TFF）の世界市場を広く調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、製品別（使い捨て式システム、再利用可能式システム、膜フィルター、ろ過付属品）分析、膜材料別（PES、ポリフッ化ビニリデン（PVDF）、ナイロン、ポリテトラフルオロエチレン（PTFE）、混合セルロースエステル・セルロースアセテート（MCE・CA））分析、技術別（精密ろ過、限外ろ過、ナノフィルトレーション、その他）分析、用途別（最終製品処理、原材料ろ過、セル分離、浄水、空気清浄）分析、地域別分析、競争状況、企業情報などの項目を掲載しています。・イントロダクション・調査手法・エグゼクティブサマリー・プレミアムインサイト・市場概要・世界のタンジェンシャルフローろ過（TFF）市場規模：製品別（使い捨て式システム、再利用可能式システム、膜フィルター、ろ過付属品）・世界のタンジェンシャルフローろ過（TFF）市場規模：膜材料別（PES、ポリフッ化ビニリデン（PVDF）、ナイロン、ポリテトラフルオロエチレン（PTFE）、混合セルロースエステル・セルロースアセテート（MCE・CA））・世界のタンジェンシャルフローろ過（TFF）市場規模：技術別（精密ろ過、限外ろ過、ナノフィルトレーション、その他）・世界のタンジェンシャルフローろ過（TFF）市場規模：用途別（最終製品処理、原材料ろ過、セル分離、浄水、空気清浄）...“The global tangential flow filtration market is projected to USD 2.8 billion by 2027 from USD 1.5 billion in 2022, at a CAGR of 13.2% during the forecast period.” The rising advantages of tangential flow filtration over normal flow filtration, increasing adoption of single-use technologies, and growing R&D spending in pharma-biotech companies. On the contrary, the high capital investments for setting up new production facilities are expected to restrain the market growth. “In 2021 the single-use systems segment accounted for the largest share of the tangential flow market.” The tangential flow filtration market is segmented into single-use systems, reusable systems,...

ラテラルフローアッセイ（LFA）コンポーネントの世界市場予測（～2027）：種類別、用途別、技術別、エンドユーザー別、地域別
MD8068-22 / MarketsandMarkets / 2022年4月1日 / マーケッツアンドマーケッツ社は、世界のラテラルフローアッセイ（LFA）コンポーネント市場規模が、2022年339百万ドルから2027年420百万ドルまで年平均4.3％成長すると予測しています。本調査資料では、ラテラルフローアッセイ（LFA）コンポーネントの世界市場を調査対象とし、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、種類別（膜、パッド、その他）分析、用途別（臨床検査、獣医診断、食品安全・環境検査、創薬・品質検査）分析、技術別（サンドイッチアッセイ、競合アッセイ、マルチプレックス検出アッセイ）分析、エンドユーザー別（医療機器メーカー、医療機器受託製造会社）分析、地域別分析、競争状況、企業情報などの項目を掲載しています。・イントロダクション・調査手法・エグゼクティブサマリー・プレミアムインサイト・市場概要・世界のラテラルフローアッセイ（LFA）コンポーネント市場規模：種類別（膜、パッド、その他）・世界のラテラルフローアッセイ（LFA）コンポーネント市場規模：用途別（臨床検査、獣医診断、食品安全・環境検査、創薬・品質検査）・世界のラテラルフローアッセイ（LFA）コンポーネント市場規模：技術別（サンドイッチアッセイ、競合アッセイ、マルチプレックス検出アッセイ）・世界のラテラルフローアッセイ（LFA）コンポーネント市場規模：エンドユーザー別（医療機器メーカー、医療機器受託製造会社）...“The global lateral flow assay components market is projected to reach USD 420 million by 2027 from USD 339 million in 2022, at a CAGR of 4.3% during the forecast period.” The high prevalence of infectious diseases worldwide, rapid growth in the geriatric population, the growing demand for point-of-care testing, the increased demand for lateral flow assay components due to COVID-19, and the rising use of home-based lateral flow assay devices are the major factors driving the growth of the lateral flow assay components market. “Membranes segment accounted for the largest share in the lateral flow assay components market.” Based...

ポイントオブケア（POC）＆迅速診断の世界市場予測（～2027）：製品別、プラットフォーム別、購入方法別、エンドユーザー別
MD2702-22 / MarketsandMarkets / 2022年3月8日 / マーケッツアンドマーケッツ社は、世界のポイントオブケア（POC）＆迅速診断市場規模が、2022年432億ドルから2027年720億ドルまで年平均10.8％成長すると予測しています。本調査レポートは、ポイントオブケア（POC）＆迅速診断の世界市場について調査し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、製品別（ぶどう糖モニタリング製品、新型コロナウイルス感染症検査製品、心血管代謝モニタリング製品、感染症検査製品、凝固監視製品）分析、プラットフォーム別（ラテラルフローアッセイ、イムノ分析、マイクロ流体、ディップスティック、分子診断）分析、購入方法別（OTC、処方箋）分析、エンドユーザー別（臨床研究室、外来治療施設、薬局・小売、病院・救急センター、家庭）分析、地域別分析、競争状況、企業情報など、以下の構成でまとめております。・イントロダクション・調査手法・エグゼクティブサマリー・プレミアムインサイト・市場概要・世界のポイントオブケア（POC）＆迅速診断市場規模：製品別（ぶどう糖モニタリング製品、新型コロナウイルス感染症検査製品、心血管代謝モニタリング製品、感染症検査製品、凝固監視製品）・世界のポイントオブケア（POC）＆迅速診断市場規模：プラットフォーム別（ラテラルフローアッセイ、イムノ分析、マイクロ流体、ディップスティック、分子診断）・世界のポイントオブケア（POC）＆迅速診断市場規模：購入方法別（OTC、処方箋）・世界のポイントオブケア（POC）＆迅速診断市場規模：エンドユーザー別（臨床研究室、外来治療施設、薬局・小売、病院・救急センター、家庭）...“The global point of care diagnostics market is expected to reach USD 72.0 billion by 2027 from an estimated USD 43.2 billion in 2022, at a CAGR of 10.8% from 2022 to 2027.” Point-of-care testing (POCT) includes screening or diagnostic tests performed outside traditional laboratories. These tests are designed to be used at or near the site where the patient is located (such as at home, in an ambulance, at a physician’s office, and other locations). POCT allows rapid and reliable diagnostic testing through which outcomes can be obtained instantly, helping physicians/patients to make decisions related to care remotely and...

電動パワーステアリングの世界市場予測（～2027）：コンポーネント別、種類別、メカニズム別、電気モーター種類別、用途別、オフハイウェイ別、EV別、EVギア種類別、地域別
AT5951-22 / MarketsandMarkets / 2022年4月21日 / マーケッツアンドマーケッツ社は、世界の電動パワーステアリング市場規模が2021年243億ドルから2027年334億ドルまで、年平均5.0％成長すると予想しています。本市場調査資料では、電動パワーステアリングの世界市場を広く調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、コンポーネント別（ステアリングコラム、センサー、ステアリングギア、メカニカルピニオン・ラック、電子制御ユニット（ECU））分析、オフハイウェイ車両別（農業用トラクター、建設機械）分析、電気モーター種類別（ブラシ付きDCモーター、ブラシレスDCモーター）分析、用途別（乗用車、商用車）分析、地域別分析、競争状況、企業情報などの項目を掲載しています。・イントロダクション・調査手法・エグゼクティブサマリー・プレミアムインサイト・市場概要・世界の電動パワーステアリング市場規模：コンポーネント別（ステアリングコラム、センサー、ステアリングギア、メカニカルピニオン・ラック、電子制御ユニット（ECU））・世界の電動パワーステアリング市場規模：オフハイウェイ車両別（農業用トラクター、建設機械）・世界の電動パワーステアリング市場規模：電気モーター種類別（ブラシ付きDCモーター、ブラシレスDCモーター）・世界の電動パワーステアリング市場規模：用途別（乗用車、商用車）...“The global electric power steering market is estimated to be at USD 24.3 billion in 2021 and is projected to grow at a CAGR of 5.0% during the forecast period to, USD 33.4 billion by 2027.” Column Assist EPS (CEPS) has proved to be the perfect solution for compact vehicles that have lesser space in the engine room because the power assist unit is located in the cabin. This system integrates the system electronics (motor, controller, and sensor) and the assist mechanism with the steering column. Around 60% of vehicles that have an EPS system feature CEPS steering systems. However,...

創薬における人工知能（AI）のグローバル市場予測（2022～2027）：ソフトウェア、サービス
HIT7445-22 / MarketsandMarkets / 2022年6月15日 / マーケッツアンドマーケッツ社は、世界の創薬における人工知能（AI）市場規模が、2022年6億ドルから2027年40億ドルまで年平均45.7％成長すると予測しています。本調査資料では、創薬における人工知能（AI）の世界市場について総合的に調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、提供別（ソフトウェア、サービス）分析、技術別（機械学習、その他技術）分析、用途別（免疫・腫瘍、神経変性疾患、心血管疾患、代謝性疾患、その他）分析、エンドユーザー別（製薬＆バイオテクノロジー企業、CRO、研究センター＆学術・政府機関）分析、地域別分析、競争状況、企業情報などの内容をまとめております。・イントロダクション・調査手法・エグゼクティブサマリー・プレミアムインサイト・市場概要・世界の創薬における人工知能（AI）市場規模：提供別（ソフトウェア、サービス）・世界の創薬における人工知能（AI）市場規模：技術別（機械学習、その他技術）・世界の創薬における人工知能（AI）市場規模：用途別（免疫・腫瘍、神経変性疾患、心血管疾患、代謝性疾患、その他）・世界の創薬における人工知能（AI）市場規模：エンドユーザー別（製薬＆バイオテクノロジー企業、CRO、研究センター＆学術・政府機関）...“The Artificial intelligence/AI in drug discovery Market is projected to reach USD 4.0 billion by 2027 from USD 0.6 billion in 2022, at a CAGR of 45.7% during the forecast period.” The growth of this market is primarily driven by factors such as the need to control drug discovery & development costs and reduce the overall time taken in this process, the rising adoption of cloud-based applications and services. On the other hand, the inadequate availability of skilled labor is key factor restraining the market growt at certain extent over the forecast period. “Services segment is estimated to hold the...

核酸単離＆精製のグローバル市場予測（～2027）：キット、試薬、機器
BT2398-22 / MarketsandMarkets / 2022年6月17日 / マーケッツアンドマーケッツ社は、世界の核酸単離＆精製市場規模が、2022年63億ドルから2027年92億ドルまで年平均7.9％成長すると予測しています。本調査資料では、核酸単離＆精製の世界市場について総合的に調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、種類別（プラスミドDNA、トータルRNA、ゲノムDNA、メッセンジャーRNA、循環核酸）分析、方法別（カラム、磁気ビーズ、試薬、その他）分析、製品別（キット、試薬、機器）分析、用途別（診断、創薬・開発、個別化医療、農業＆動物研究、その他）分析、地域別分析、競争状況、企業情報などの内容をまとめております。・イントロダクション・調査手法・エグゼクティブサマリー・プレミアムインサイト・市場概要・世界の核酸単離＆精製市場規模：種類別（プラスミドDNA、トータルRNA、ゲノムDNA、メッセンジャーRNA、循環核酸）・世界の核酸単離＆精製市場規模：方法別（カラム、磁気ビーズ、試薬、その他）・世界の核酸単離＆精製市場規模：製品別（キット、試薬、機器）・世界の核酸単離＆精製市場規模：用途別（診断、創薬・開発、個別化医療、農業＆動物研究、その他）...“The global nucleic acid isolation and purification market is projected to reach USD 9.2 billion by 2027 from USD 6.3billion in 2022, at a CAGR of 7.9% during the forecast period.” The growth of this market can majorly be attributed to the increasing R&D activities as well as technological advancements and increasing automation. The emerging economies, improving regulatory and reimbursement scenario, and the growing adoption of molecular diagnostics and personalized medicines are expected to offer a wide range of growth opportunities for players in the market. However, the high cost of automated instruments is expected to hinder the growth of...

バイオ除染のグローバル市場予測（～2027）：機器、サービス、消耗品
MD7164-22 / MarketsandMarkets / 2022年6月22日 / マーケッツアンドマーケッツ社は、世界のバイオ除染市場規模が、2022年159百万ドルから2027年227百万ドルまで年平均7.3％成長すると予測しています。本調査資料では、バイオ除染の世界市場について総合的に調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、製品・サービス別（機器、サービス、消耗品）分析、薬剤別（過酸化水素、二酸化塩素、過酢酸、二酸化窒素）分析、種類別（部屋除染、チャンバー除染）分析、エンドユーザー別（製薬＆医療機器製造会社、ライフサイエンス＆バイオテクノロジー研究機関、病院＆医療施設）分析、地域別分析、競争状況、企業情報などの内容をまとめております。・イントロダクション・調査手法・エグゼクティブサマリー・プレミアムインサイト・市場概要・世界のバイオ除染市場規模：製品・サービス別（機器、サービス、消耗品）・世界のバイオ除染市場規模：薬剤別（過酸化水素、二酸化塩素、過酢酸、二酸化窒素）・世界のバイオ除染市場規模：種類別（部屋除染、チャンバー除染）・世界のバイオ除染市場規模：エンドユーザー別（製薬＆医療機器製造会社、ライフサイエンス＆バイオテクノロジー研究機関、病院＆医療施設）...“The global bio decontamination market is projected to reach USD 227 million by 2027 from USD 159 million in 2022, at a CAGR of 7.3% from 2022 to 2027.” The increasing incidence of hospital-acquired infections, the increasing outsourcing of bio decontamination services, and presence of stringent regulation in pharmaceutical and medical device industry are the major factors driving the bio decontamination market. The chamber decontaminationsegment accounted for the highest growth rate in the bio decontamination market, by product, during the forecast period The global bio decontamination market is segmented into room decontamination and chamber decontamination based on type.The chamber decontaminationis...

軟部組織修復の世界市場予測（～2027）：製品別、用途別
MD3215-22 / MarketsandMarkets / 2022年3月29日 / マーケッツアンドマーケッツ社は、世界の軟部組織修復市場規模が、2022年136億ドルから2027年172億ドルまで年平均4.7％成長すると予測しています。本調査資料では、軟部組織修復の世界市場を調査対象とし、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、製品別（組織パッチ/メッシュ、腹腔鏡器具）分析、用途別（ヘルニア修復、皮膚修復、整形外科修復、歯科修復、豊胸）分析、エンドユーザー別（病院、クリニック、その他）分析、地域別分析、競争状況、企業情報などの項目を掲載しています。・イントロダクション・調査手法・エグゼクティブサマリー・プレミアムインサイト・市場概要・世界の軟部組織修復市場規模：製品別（組織パッチ/メッシュ、腹腔鏡器具）・世界の軟部組織修復市場規模：用途別（ヘルニア修復、皮膚修復、整形外科修復、歯科修復、豊胸）・世界の軟部組織修復市場規模：エンドユーザー別（病院、クリニック、その他）・世界の軟部組織修復市場規模：地域別...“MarketsandMarkets expects the soft tissue repair market is projected to reach USD 17.2Billion by 2027 from USD 13.6Billion in 2022, at a CAGR of 4.7% during the forecast period.” Growth in this market is mainly driven by Increasing aging population and obesity rate, growing incidence of sports injuries, strong focus on R&D leading to the launch of technologically advanced products, and increasing volume of surgeries and growing prevalence of severe trauma injuries. This, in turn, unfavorable reimbursement scenario and high price of soft tissue repair products and the rising cost of surgical procedures are the key factors restraining the growth...

外来用EHRのグローバル市場予測（～2027）：クラウドベース、オンプレミス
HIT5227-22 / MarketsandMarkets / 2022年6月16日 / マーケッツアンドマーケッツ社は、世界の外来用EHR市場規模が、2022年57億ドルから2027年77億ドルまで年平均6.1％成長すると予測しています。本調査資料では、外来用EHRの世界市場について総合的に調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、産業洞察、デリバリー方式別（クラウドベース、オンプレミス）分析、用途別（診療管理、患者管理、電子処方、集団健康管理、その他）分析、診療規模別（大規模、中小規模、個人）分析、エンドユーザー別（病院所属外来センター、独立センター）分析、地域別分析、競争状況、企業情報などの内容をまとめております。・イントロダクション・調査手法・エグゼクティブサマリー・プレミアムインサイト・市場概要・産業洞察・世界の外来用EHR市場規模：デリバリー方式別（クラウドベース、オンプレミス）・世界の外来用EHR市場規模：用途別（診療管理、患者管理、電子処方、集団健康管理、その他）・世界の外来用EHR市場規模：診療規模別（大規模、中小規模、個人）...“The global ambulatory EHR market is projected to reach USD 5.7 billion in 2022 to USD 7.7 billion by 2027, at a CAGR of 6.1%during the forecast period.” Growth in this market is driven by the opportunities provided by the market such as increasing demand for cloud-based ambulatory EHR market, and shift towards patient-centric healthcare delivery. However, the interoperability issues & data security concernsare some of the challenges that are expected to limit the growth of the market to a certain extentduring the forecast period. “Cloud-basedwasthe fastest-growing segment in thedelivery mode ofambulatory EHR marketin 2021” Cloud-based segmentis projected to growth...

◆H&Iグローバルリサーチ株式会社のお客様（例）◆